Literature DB >> 29399281

Ratio of mean platelet volume to platelet count is a potential surrogate marker predicting liver cirrhosis.

Hiroya Iida1, Masaki Kaibori1, Kosuke Matsui1, Morihiko Ishizaki1, Masanori Kon1.   

Abstract

AIM: To provide a simple surrogate marker predictive of liver cirrhosis (LC).
METHODS: Specimens from 302 patients who underwent resection for hepatocellular carcinoma between January 2006 and December 2012 were retrospectively analyzed. Based on pathologic findings, patients were divided into groups based on whether or not they had LC. Parameters associated with hepatic functional reserve were compared in these two groups using Mann-Whitney U-test for univariate analysis. Factors differing significantly in univariate analyses were entered into multivariate logistic regression analysis.
RESULTS: There were significant differences between the LC group (n = 100) and non-LC group (n = 202) in prothrombin activity, concentrations of alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, cholinesterase, type IV collagen, hyaluronic acid, indocyanine green retention rate at 15 min, maximal removal rate of technitium-99m diethylene triamine penta-acetic acid-galactosyl human serum albumin and ratio of mean platelet volume to platelet count (MPV/PLT). Multivariate analysis showed that prothrombin activity, concentrations of alanine aminotransferase, aspartate aminotransferase, total bilirubin and hyaluronic acid, and MPV/PLT ratio were factors independently predictive of LC. The area under the curve value for MPV/PLT was 0.78, with a 0.8 cutoff value having a sensitivity of 65% and a specificity of 78%.
CONCLUSION: The MPV/PLT ratio, which can be determined simply from the complete blood count, may be a simple surrogate marker predicting LC.

Entities:  

Keywords:  Hepatic functional reserve; Liver cirrhosis; Liver fibrosis; Mean platelet volume; Platelet count

Year:  2018        PMID: 29399281      PMCID: PMC5787688          DOI: 10.4254/wjh.v10.i1.82

Source DB:  PubMed          Journal:  World J Hepatol


Core tip: Although liver biopsy is considered the gold standard in the diagnosis of liver fibrosis and cirrhosis, liver biopsy is an invasive procedure, with attendant morbidity. Less invasive procedures are needed in the diagnosis of liver cirrhosis. Multivariate analysis showed that the mean platelet volume to platelet count ratio was independently predictive of liver cirrhosis. This ratio, which can be determined from a routine complete blood count, may be a simple surrogate marker predicting liver cirrhosis.

INTRODUCTION

Mean platelet volume (MPV) is a machine-calculated measurement of average platelet size, usually included in complete blood count testing. Normal MPV ranges from 7.5 fL to 11.5 fL. Because average platelet size is directly proportional to the numbers of platelets produced, MPV is indicative of platelet production in bone marrow. Moreover, MPV is higher when there is destruction of platelets, as observed in patients with inflammatory bowel disease, immune thrombocytopenic purpura, myeloproliferative diseases and Bernard-Soulier syndrome[1]. MPV may also be higher in patients with pre-eclampsia and those recovering from transient bone marrow hypoplasia[2]. In contrast, abnormally low MPV values are indicative of thrombocytopenia because of impaired platelet production, as observed in patients with aplastic anemia. Several studies have reported that liver cirrhosis (LC) and fibrosis are related to MPV[3-6]. Increased MPV, as well as decreased platelet count (PLT), were found to reflect a greater degree of fibrosis. These findings suggested that the ratio of MPV to PLT may correlate strongly with the degree of liver fibrosis. This study was, therefore, designed to determine whether liver fibrosis and LC are associated with the MPV/PLT ratio or not.

MATERIALS AND METHODS

This retrospective study assessed samples obtained from 302 patients who underwent liver resection for hepatocellular carcinoma (HCC) between January 2006 and December 2012. All patients were assessed pathologically by stage of fibrosis in nontumor liver tissue using the new Inuyama classification[7]. F0 was defined as no fibrosis (n = 22), F1 as chronic hepatitis with fibrous portal expansion (n = 67), F2 as chronic hepatitis with bridging fibrosis (n = 62), F3 as chronic hepatitis with bridging fibrosis and architectural distortion (n = 51), and F4 as LC with tendency toward nodular formation throughout the whole area. Patients classified as F0-F3 were assigned to the non-LC group (n = 202), and those classified as F4 to the LC group (n = 100). Parameters associated with hepatic functional reserve were assessed in all patients; these included: MPV, PLT, and the MPV/PLT ratio; prothrombin activity (PT); concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, cholinesterase, type IV collagen, and hyaluronic acid; indocyanine green retention rate at 15 min (ICGR15); and, the maximal removal rate of technitium-99m diethylene triamine penta-acetic acid (99mTc-DTPA)-galactosyl human serum albumin (GSA-Rmax), a marker of hepatic functional reserve, as determined by scintigraphy[8,9]. These factors were compared between the LC and non-LC groups. Multivariate regression analysis was performed to identify factors independently predictive of LC, and cutoff values were calculated. In addition, patients were divided by fibrosis stage (F0-F4), and these parameters were compared among the five subgroups. Comorbidities that could be associated with an increase or decrease in the MPV/PLT ratio, such as inflammatory bowel disease, immune thrombocytopenic purpura, myeloproliferative disease or Bernard-Soulier syndrome, were not observed in any of the patients.

Statistical analysis

Parameters predictive of hepatic functional reserve in the LC and non-LC groups were compared using the Mann-Whitney U-test. Factors differing significantly in univariate analyses were entered into multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves were used to calculate areas under the curve (AUC) and cutoff values. All analyses were performed using JMP 9 statistical analysis software (SAS Institute Inc., Cary, NC, United States), with a P value of < 0.05 defined as statistically significant.

RESULTS

There were 161 patients with hepatitis C and 53 patients with hepatitis B. The remaining 88 patients were negative for hepatitis B and C. The average age was 69.6 ± 9.7 years in the non-LC group and 68.2 ± 7.6 years in the LC group (P = 0.21). The ratio of males to females was larger in the non-LC group, with 164 (81.2%) male and 38 (18.8%) female patients; there were 69 (69.0%) male and 31 (31.0%) female patients in the LC group (P = 0.02). Table 1 compares parameters (univariate analysis) between the LC and non-LC groups. The rate of hepatitis C was greater in the LC group than in the non-LC group (P < 0.001). The Edmondson-Steiner grade[10] for HCC grade I was a little smaller and for grade II a little larger in the LC group; however, the difference was not significant (P = 0.07). The average PLT was 11.6 ± 4.6 × 104/μL and 18.9 ± 8.1 × 104/μL, respectively, and the average MPV was 10.8 ± 0.9 fL and 10.2 ± 0.9 fL, respectively (P < 0.05 for each). The MPV/PLT ratio was significantly higher in the LC group than in the non-LC group (1.10 ± 0.51 vs 0.64 ± 0.30, P < 0.05). Other factors associated with hepatic functional reserve also differed significantly between the two groups, including PT, the concentrations of AST, ALT, total bilirubin, albumin, cholinesterase, type IV collagen and hyaluronic acid, ICGR15 and GSA-Rmax (P < 0.05 for each).
Table 1

Univariate analysis of factors in non-liver cirrhosis and liver cirrhosis groups

Non-LC group, n = 202LC group, n = 100P-value
Etiology
HBV43 (21.2%)10 (10.0%)
HCV89 (44.1%)72 (72.0%)
NBNC70 (34.7%)18 (18.0%)< 0.001
Edmonson-Steiner grade
I30 (30.0%)36 (17.8%)0.07
II64 (64.0%)151 (74.8%)
III4 (4.0%)13 (6.4%)
IV2 (2.0%)2 (1.0%)
PLT, × 104/μL18.9 ± 8.111.6 ± 4.6< 0.0001
MPV, fL10.2 ± 0.910.8 ± 0.9< 0.0001
MPV/PLT ratio0.64 ± 0.301.10 ± 0.51< 0.0001
PT, %92.9 ± 11.782.5 ± 11.1< 0.0001
AST, IU/L42 ± 2651 ± 23< 0.0001
ALT, IU/L40 ± 3047 ± 330.02
Total-bilirubin, mg/dL0.67 ± 0.230.90 ± 0.34< 0.0001
Albumin, g/dL3.8 ± 0.53.6 ± 0.40.01
Cholinesterase, IU/L235 ± 80193 ± 60< 0.0001
Type 4 collagen, ng/mL6.3 ± 2.49.1 ± 4.40.04
Hyaluronic acid, ng/mL147 ± 179312 ± 318< 0.0001
ICGR15, %14.1 ± 8.322.1 ± 12.1< 0.0001
GSA Rmax, mg/min0.62 ± 0.210.44 ± 0.17< 0.0001

All results reported as mean ± standard deviation. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GSA-Rmax: Maximal removal rate of 99mTc-DTPA-galactosyl human serum albumin; HBV: Positive for hepatitis B antigen; HCV: Positive for hepatitis C antibody; ICGR15: Indocyanine green retention rate at 15 min; LC: Liver cirrhosis; MPV: Mean platelet volume; PLT: Platelet count; PT: Prothrombin activity.

Univariate analysis of factors in non-liver cirrhosis and liver cirrhosis groups All results reported as mean ± standard deviation. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GSA-Rmax: Maximal removal rate of 99mTc-DTPA-galactosyl human serum albumin; HBV: Positive for hepatitis B antigen; HCV: Positive for hepatitis C antibody; ICGR15: Indocyanine green retention rate at 15 min; LC: Liver cirrhosis; MPV: Mean platelet volume; PLT: Platelet count; PT: Prothrombin activity. Table 2 shows multivariate analysis of factors predictive of LC in these patients. MPV/PLT ratio, PT, and concentrations of AST, ALT, total bilirubin and hyaluronic acid were independent predictors of LC. The highest odds ratio was 3.71 for the MPV/PLT ratio. Although albumin, cholinesterase and type IV collagen concentrations, as well as ICGR15 and GSA-Rmax, were also predictors of LC on univariate analysis, they were not independently predictive on multivariate analysis.
Table 2

Multivariate analysis of factors predicting liver cirrhosis

Odds ratioP-value95%CI
MPV/PLT ratio≥ 0.71, n = 1513.71< 0.00011.94-7.28
< 0.71, n = 151
PT, %≥ 89.0, n = 1512.680.00181.44-5.06
< 89.0, n = 151
AST, IU/L≥ 39, n = 1553.300.011.30-9.09
< 39, n = 147
ALT, IU/L≥ 34, n = 1532.570.041.02-7.09
< 34, n = 149
Total-bilirubin, mg/dL≥ 0.7, n = 1771.890.041.00-3.61
< 0.7, n = 125
Albumin, g/dL≥ 3.8, n = 1680.950.890.47-1.89
< 3.8, n = 134
Cholinesterase, IU/L≥ 211, n = 1520.980.960.48-1.98
< 211, n = 150
Type 4 collagen, ng/mL≥ 6.5, n = 1660.950.860.51-1.72
< 6.5, n = 136
Hyaluronic acid, ng/mL≥ 124, n = 1532.280.0081.23-4.26
< 124, n = 149
ICGR15, %≥ 14.3, n = 1511.400.300.72-2.68
< 14.3, n = 151
GSA Rmax, mg/min≥ 0.555, n = 1511.510.240.75-3.04
< 0.555, n = 151

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CI: Confidence interval; GSA-Rmax: Maximal removal rate of 99mTc-DTPA-galactosyl human serum albumin; ICGR15: Indocyanine green retention rate at 15 min; MPV: Mean platelet volume; PLT: Platelet count; PT: Prothrombin activity.

Multivariate analysis of factors predicting liver cirrhosis ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CI: Confidence interval; GSA-Rmax: Maximal removal rate of 99mTc-DTPA-galactosyl human serum albumin; ICGR15: Indocyanine green retention rate at 15 min; MPV: Mean platelet volume; PLT: Platelet count; PT: Prothrombin activity. The ROC curves of all six independently predictive factors (MPV/PLT ratio, PT, and concentrations of AST, ALT, total bilirubin and hyaluronic acid) are shown in Figure 1. Calculation of AUC for all six factors showed that the MPV/PLT ratio had the highest AUC (0.78). A cutoff value of 0.8 had a sensitivity of 65% and a specificity of 78% in predicting LC. This ratio was a better predictor of LC than other parameters of hepatic functional reserve.
Figure 1

Receiver operating characteristic curve analysis of parameters differing significantly in the liver cirrhosis and non-liver cirrhosis groups on multivariate analysis. The area under the curve of MPV/PLT was the highest. A MPV/PLT ratio of 0.8 had a sensitivity of 65% and a specificity of 78%. MPV/PLT: Mean platelet volume to platelet count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin activity.

Receiver operating characteristic curve analysis of parameters differing significantly in the liver cirrhosis and non-liver cirrhosis groups on multivariate analysis. The area under the curve of MPV/PLT was the highest. A MPV/PLT ratio of 0.8 had a sensitivity of 65% and a specificity of 78%. MPV/PLT: Mean platelet volume to platelet count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin activity. Patients were also divided by individual fibrosis stage and MPV/PLT ratio determined for each stage. The average MPV/PLT ratios for patients classified as F0-1, F2, F3 and F4 were 0.54 ± 0.24, 0.65 ± 0.29, 0.79 ± 0.35 and 1.10 ± 0.51, respectively, with each pairwise difference being statistically significant (Figure 2).
Figure 2

Relationship between MPV/PLT ratio and fibrosis stage. There were significant differences between each pair of stages. MPV/PLT: Mean platelet volume to platelet count.

Relationship between MPV/PLT ratio and fibrosis stage. There were significant differences between each pair of stages. MPV/PLT: Mean platelet volume to platelet count. Additionally, we examined the correlation between the MPV/PLT ratio and the pathological inflammation level according to the new Inuyama classification. The average MPV/PLT ratios for patients classified as A0, A1, A2 and A3 were 0.68 ± 0.21, 0.70 ± 0.45, 0.82 ± 0.39 and 0.73 ± 0.10, respectively. There was no significant correlation between MPV/PLT and pathological inflammation level (P = 0.214).

DISCUSSION

LC is a result of advanced liver disease, in which normal liver tissue is replaced by fibrotic tissue. These changes lead to loss of liver function. LC is most frequently caused by alcoholism, infection with hepatitis B and hepatitis C viruses, and fatty liver disease, but it may have many other causes. LC arising from nonalcoholic steatohepatitis (NASH) was recently shown to be a worldwide problem. The standard method of diagnosing LC is liver biopsy. However, liver biopsy is an invasive procedure and cannot be performed on patients with severe ascites or severe coagulation disorders. Several studies have, therefore, assessed surrogate markers in blood predictive of LC; these include FibroTest (FibroSure) and the AST platelet ratio index[11]. In addition, elastographic methods, such as FibroScan, have been reported to be noninvasive methods of predicting LC[12,13]. We could not compare these methods with the MPV/PLT ratio because we do not have these examination devices. MPV may be another predictor of LC. Higher MPV has been reported in patients with hepatitis B[14], and LC, fibrosis level and MPV have been reported to correlate in patients with chronic hepatitis B[3-5]. MPV may also be predictive of LC in patients with chronic hepatitis C[6]. MPV has been associated not only with fibrosis stage but with degree of liver inflammation[15]. For example, higher MPV has been observed in patients with NASH[16], and MPV has been found to correlate with the presence of nonalcoholic fatty liver disease (NAFLD)[17], although another study reported no correlation[18]. In addition, MPV may or may not correlate with insulin resistance, which is closely related to NAFLD[19,20]. To date, however, the relationship between NAFLD and MPV has not been determined. MPV has been reported to strongly correlate with the prognosis of patients with non-small cell lung cancer[21]. In addition, high MPV and MPV/PLT have been found to be associated with a high risk for HCC[22,23]. An examination of the correlation between MPV/PLT ratio and postoperative prognosis of patients undergoing hepatic resection for HCC found that the MPV/PLT ratio was unrelated to overall or recurrence-free survival rate after resection. This study had several limitations, including its retrospective design, performance at a single center and small sample size. Moreover, all patients included had undergone resection for HCC. Therefore, the results should not be generalized to patients without HCC before verification. Prospective, multicenter studies with large numbers of patients are needed to confirm these findings. In conclusion, we found that the MPV/PLT ratio was predictive of LC, suggesting that this ratio may be a simple surrogate marker predictive of LC.

ARTICLE HIGHLIGHTS

Background

Several noninvasive methods for predicting cirrhosis have been reported, but liver biopsy is the only method for obtaining a definitive diagnosis. However, liver biopsy is invasive, and a noninvasive diagnostic method is desirable. Mean platelet volume (MPV), the size of platelets, can be determined from routine complete blood count data of blood samples. Generally, if bone marrow hematopoietic function decreases, MPV decreases. In contrast, if spleen function increases, new platelets are made rapidly and MPV increases. In recent years, the relationship between MPV and liver disease has attracted attention.

Research frontiers

There are reports that MPV correlates with liver function, and there are reports that MPV is related to the incidence of HCC. However, there is no report to evaluate the correlation between MPV/platelet count (PLT) and liver function, so we undertook this study.

Innovations and breakthroughs

The authors studied only patients who were diagnosed with cirrhosis histopathologically after liver resection. The MVP/PLT ratio could predict cirrhosis more sensitively than other general liver function tests.

Applications

The MPV/PLT ratio also correlated with the degree of hepatic fibrosis according to the Inuyama classification. The authors examined the relationship between prognosis after hepatic resection of hepatocellular carcinoma and the value of the MPV/PLT ration, but unfortunately no correlation was found.

Terminology

MPV is the size of platelets and can be determined from routine complete blood count data of blood samples. Liver cirrhosis and fibrosis are related to MPV.
  22 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease.

Authors:  Nur Arslan; Balahan Makay
Journal:  J Pediatr Endocrinol Metab       Date:  2010-08       Impact factor: 1.634

3.  Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease.

Authors:  Mehmet Celikbilek; Sebnem Gürsoy; Kemal Deniz; Ahmet Karaman; Gökmen Zararsiz; Alper Yurci
Journal:  Platelets       Date:  2012-05-30       Impact factor: 3.862

4.  The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population.

Authors:  Woul-Young Shin; Dong-Hyuk Jung; Jae-Yong Shim; Hye-Ree Lee
Journal:  Platelets       Date:  2011-07-13       Impact factor: 3.862

5.  Increased mean platelet volume in patients with acute coronary syndromes.

Authors:  Giuseppe Lippi; Luca Filippozzi; Gian Luca Salvagno; Martina Montagnana; Massimo Franchini; Gian Cesare Guidi; Giovanni Targher
Journal:  Arch Pathol Lab Med       Date:  2009-09       Impact factor: 5.534

6.  The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Mevlut Kurt; Ibrahim Koral Onal; Abdurrahim Yee Sayilir; Yavuz Beyazit; Erkin Oztas; Murat Kekilli; Nesrin Turhan; Kerem Karaman; Meral Akdogan
Journal:  Hepatogastroenterology       Date:  2012 Jul-Aug

7.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

8.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.

Authors:  J Foucher; E Chanteloup; J Vergniol; L Castéra; B Le Bail; X Adhoute; J Bertet; P Couzigou; V de Lédinghen
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

9.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

10.  Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis.

Authors:  Tugrul Purnak; Sehmus Olmez; Serkan Torun; Cumali Efe; Abdurrahim Sayilir; Ersan Ozaslan; Ilyas Tenlik; Ismail Hakki Kalkan; Yavuz Beyazit; Osman Yuksel
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-05-07       Impact factor: 2.947

View more
  5 in total

1.  The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B.

Authors:  Li-Kun Zhong; Guo Zhang; Shuang-Yan Luo; Wu Yin; Huai-Yu Song
Journal:  J Clin Lab Anal       Date:  2020-05-04       Impact factor: 2.352

2.  Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease: A cross-sectional study.

Authors:  Wen-Jie Zhou; Jing Yang; Ge Zhang; Zheng-Qiang Hu; Yong-Mei Jiang; Fan Yu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Mean Platelet Volume-to-Platelet Count Ratio, Mean Platelet Volume-to-Lymphocyte Ratio, and Red Blood Cell Distribution Width-Platelet Count Ratio as Markers of Inflammation in Patients with Ascending Thoracic Aortic Aneurysm.

Authors:  Yusuf Kenan Tekin; Gülacan Tekin
Journal:  Braz J Cardiovasc Surg       Date:  2020-04-01

4.  Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales.

Authors:  Agata Michalak; Halina Cichoż-Lach; Małgorzata Guz; Joanna Kozicka; Marek Cybulski; Witold Jeleniewicz; Andrzej Stepulak
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

5.  AST-to-Platelet Ratio Index as Potential Early-Warning Biomarker for Sepsis-Associated Liver Injury in Children: A Database Study.

Authors:  Jiaying Dou; Yiping Zhou; Yun Cui; Min Chen; Chunxia Wang; Yucai Zhang
Journal:  Front Pediatr       Date:  2019-08-21       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.